Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Targeted disruption of the t cell receptor

A cell receptor and cell technology, applied in the field of human cell genome modification, which can solve the problem of inability to generate graft-versus-host disease cells

Pending Publication Date: 2018-11-09
SANGAMO BIOSCIENCES INC
View PDF150 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, knockdown of the TCR will generate cells that are unable to mount a graft-versus-host disease (GVHD) response once introduced into a patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Targeted disruption of the t cell receptor
  • Targeted disruption of the t cell receptor
  • Targeted disruption of the t cell receptor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0192] Example 1: Design of TCR-specific nucleases

[0193] TCR-specific ZFNs were constructed to achieve site-specific introduction of double-strand breaks located at the TCRα (TCRA) gene. Principally by Urnov et al. (2005) Nature 435(7042):646-651, Lombardo et al. (2007) Nat Biotechnol. Nov; 25(11):1298-306, and U.S. Patent Publication Nos. 2008-0131962, 2015-016495 , 2014-0120622, 2014-0301990 and US Pat. No. 8,956,828 to design ZFNs. ZFN pairs target different sites in the constant region of the TCRA gene (see Figure 1). The recognition helices and target sequences for exemplary ZFN pairs are shown in Table 1 below. The target sites of TCRA zinc finger design are shown in the first column. Nucleotides in the target site targeted by the ZFP recognition helix are indicated in upper case; nucleotides not targeted are indicated in lower case. The linker used to connect the FokI nuclease domain and the ZFP DNA binding domain is also shown (see, US Patent Publication No. 201...

Embodiment 2

[0204] Embodiment 2: in vitro nuclease activity

[0205] The ZFNs described in Table 1 were used to test nuclease activity in K562 cells. To test for cleavage activity, plasmids encoding the above human TCRA-specific ZFN pairs were transfected into K562 cells together with plasmids or mRNA. K562 cells were obtained from the American Type Culture Collection and grown as recommended in RPMI medium (Invitrogen) supplemented with 10% quantitative fetal bovine serum (FBS, Cy clone). For transfection, the ORFs of the active nucleases listed in Table 1 were cloned into expression vectors optimized for mRNA production containing 5' and 3' UTRs and a synthetic poly-A signal. mRNA was generated using the mMessage mMachine T7 Ultra kit (Ambion) following the manufacturer's instructions. In vitro synthesis of nuclease mRNA using a pVAX-based vector containing a T7 promoter, an appropriate nuclease, and a poly-A motif, or a pGEM-based vector, or a PCR amplicon for in vitro The poly-A ta...

Embodiment 3

[0217] Example 3: TCRA-specific ZFN activity in T cells

[0218]The nuclease activity of TCRA-specific ZFN pairs was also tested in human T cells. ZFN-encoding mRNAs were transfected into purified T cells. Briefly, T cells were obtained from leukopheresis products and purified using Miltenyi's CliniMACS system (CD4 and CD8 dual selection). These cells were then activated using Dynabeads (ThermoFisher) according to the manufacturer's protocol. Three days after activation, cells were transfected with three doses of mRNA (60, 120 and 250 μg / mL) using a Maxcyte electrotransformer (Maxcyte Company), OC-100, 30e6 cells / mL, and a volume of 0.1 mL. On day 10 after transfection, cells were analyzed for ontarget TCRA modification using deep sequencing (Miseq, Illumina). Cell viability and cell growth (total cell doublings) were measured throughout 13-14 days in culture. In addition, at day 10 of culture for CD3 staining, TCR was measured on the cell surface of treated cells using st...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are methods and compositions for inactivating TCR genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and / or cells comprising nucleases are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, includinglymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenousTCR and / or cells comprising exogenous TCR are also provided.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 269,365, filed December 18, 2015, and U.S. Provisional Application No. 62 / 306,500, filed March 10, 2016, the disclosures of which are incorporated herein by reference in their entirety. technical field [0003] The present disclosure is in the field of genome modification of human cells, including lymphocytes and stem cells. Background technique [0004] Gene therapy holds great potential for a new era in human therapeutics. These approaches will enable the treatment of conditions not addressed by standard medical practice. Gene therapy can include many variations of gene editing techniques, such as disruption and correction of genetic loci, and insertion of expressible transgenes that can be controlled by fusion of a specific exogenous promoter for the transgene, or by the presence of Endogenous promoter control at the insertion locus site. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/15A61K35/17A61K35/545C07K14/705C12N9/22C12N15/62C12N5/0783C12N5/0789C12N5/10
CPCC12N9/16C12N15/52C12N15/62A61P35/00C12N5/0636C12N5/0603C12N5/0606C12N5/0696
Inventor G·K·李D·帕斯乔恩张雷
Owner SANGAMO BIOSCIENCES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com